Activation of p53 with agents such as low-dose actinomycin D,30 MDM2 antagonists,31 or other low-dose DNA damaging agents32 have been shown to induce selective p53 dependent G2 arrest in normal cells without arresting tumour cells, thus permitting selective killing of p53 deficient tumour cells. The gene discussed is TP53; the disease is neoplasm.